CDNA · CareDx, Inc.

AlloSeq Nano delivers rapid, high‑resolution HLA and ABO genotyping in a single assay through a streamlined, long‑read workflow designed for transplant and donor typing laboratories. CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026. AlloSeq Nano is an innovation developed by CareDx to deliver high‑resolution HLA genotyping in under three hours with streamlined long‑read library prep workflow, rapid assay turnaround, robust performance, and enhanced resolution. In early access testing, Alloseq Nano’s single-step amplification and prep workflow required approximately 45 minutes of hands‑on time to

Transaction Expected to Sharpen CareDx’s Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility, Simplify Operating Model, and Support AEBITDA Margin Expansion Expects First Quarter Testing Services Revenue Growth of Approximately 48% Year Over Year, Testing Volume Growth of Approximately 17% Year-Over-Year CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for cash consideration of $170 million. The transaction has been approved by the boards of directors of both companies. CareDx also announced today preliminary financial results for the first quarter of 2026. CareDx’s Lab Products business consists of

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com . To participate in the live conference call via telephone, register here . Upon registering, a dial-in number and unique PIN will be provided. About CareDx CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing

First-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the 2026 Precision Medicine World Conference CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world evidence development. VANTx is designed for secure, scalable cohort analysis across longitudinal patient timelines that enables the evaluation of treatment trends, patient outcomes, and practice patterns. The platform is intended to support clinicians, transplant programs, and pharma partners in testing hypotheses to generate actionable

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an aggregate of 82,137 shares of common stock. The RSU awards were made pursuant to the Company’s 2016 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniversary of each employee’s vesting commencement date, and 1/16th of the RSUs vesting on each date that is three (3) months thereafter subject to each employee’s continued service through each vesting date. CareDx is providing this information in accordance with

Kennedy brings seven years of public company CFO experience CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company’s Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company’s finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contract development and manufacturing organization (CDMO). Kennedy has served as our Chief Operating Officer since September 2024. Prior to joining us, Kennedy served as CFO at PharmaLogic Holdings Corp from April 2022 to September 2024. At Veracyte, Kennedy served in various roles from December 2016 to May

Full Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year Expects Full Year 2026 Revenue of $420 Million to $444 Million CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $108 million, an increase of 25% year-over-year Testing services revenue of $78 million, an increase of 23% year-over-year, and testing services volume of approximately 53,000, an increase of 17% year-over-year Patient and digital solutions revenue of $16.8 million and product revenue of $13.3 million, representing year-over-year growth of 47% and 17%, respectively Average revenue per test of approximately $1,480 including approximately $5 million in prior

CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the Raymond James 47 th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026. About CareDx CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com . Investor Relations Caroline Corner [email protected] Source:

AlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCT Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced pivotal clinical validation results of AlloHeme™, a non-invasive, next‑generation sequencing (NGS)–based, and artificial intelligence (AI)-powered monitoring test designed to predict relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) following allogeneic hematopoietic cell transplant (HCT). This approach enables the detection of emerging relapse signals earlier than traditional bone marrow-based

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com . To participate in the live conference call via telephone, register here . Upon registering, a dial-in number and unique PIN will be provided. About CareDx – The Transplant Company CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and